IGC Pharma
31 hedge funds and large institutions have $2.37M invested in IGC Pharma in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
172% more capital invested
Capital invested by funds: $872K → $2.37M (+$1.5M)
100% more call options, than puts
Call options by funds: $116K | Put options by funds: $58K
55% more funds holding
Funds holding: 20 → 31 (+11)
2.84% more ownership
Funds ownership: 1.06% → 3.9% (+2.8%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$642K |
| 2 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
+$304K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$281K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$133K |
| 5 |
VF
Virtu Financial
New York
|
+$73.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$39.1K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$28.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$12K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$3.53K |
| 5 |
FANJ
Financial Architects (New Jersey)
Marlton,
New Jersey
|
-$3K |
IGC Hedge Fund Activity: Q2 2019 in Review
31 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q2 2019, worth a combined $2.37M — up 172% from $872K a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IGC positions and 5 closed out — a net gain of 11 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $642K. The largest seller was Morgan Stanley, cutting an estimated $39.1K.
- 31 institutional investors held IGC Pharma (IGC) as of Q2 2019, up from 20 in Q1 2019.
- Funds reported $2.37M of IGC Pharma stock for Q2 2019, up 172% quarter-over-quarter.
- 16 funds opened new IGC Pharma positions in Q2 2019 and 5 closed out, a net change of +11 holders.
- The largest IGC Pharma buyer in Q2 2019 was Vanguard Group, an estimated $642K added.
- The largest IGC Pharma seller in Q2 2019 was Morgan Stanley, an estimated $39.1K sold.
Based on aggregated 13F filings for Q2 2019.